LTRN

3.24

1.57% 0.05

Handel nachbörslich: 3.28 0.04 +1.23%

Lantern Pharma Inc (LTRN)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$3.19

Offen:

$3.2

24-Stunden-Volumen:

53,678

Relative Volume:

0.47

Marktkapitalisierung:

$36.24M

Einnahmen:

Nettoeinkommen (Verlust:

$-19.25M

KGV:

-1.8202

EPS:

-1.78

Netto-Cashflow:

$-17.87M

1W Leistung:

-13.37%

1M Leistung:

+0.93%

6M Leistung:

+1.89%

1J Leistung:

+0.93%

1-Tages-Spanne:

$3.20

$3.4699

1-Wochen-Bereich:

$3.19

$3.78

52-Wochen-Spanne:

$2.55

$6.118

Lantern Pharma Inc Stock (LTRN) Company Profile

Firmenname

Lantern Pharma Inc

Sektor

Healthcare (1134)

Branche

Biotechnology (634)

Telefon

972-277-1136

Adresse

1920 MCKINNEY AVENUE, DALLAS, TX

Mitarbeiter

Twitter

@lanternpharma

Nächster Verdiensttermin

2025-08-08

Neueste SEC-Einreichungen

LTRN's Discussions on Twitter

Vergleichen Sie LTRN mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
LTRN Lantern Pharma Inc	3.24	35.68M	0	-19.25M	-17.87M	-1.78
VRTX Vertex Pharmaceuticals Inc	447.38	114.05B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	748.71	78.80B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	396.04	51.80B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	847.05	53.08B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	166.55	42.33B	447.02M	-1.18B	-906.14M	-6.1812

Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2021-10-07	Eingeleitet	H.C. Wainwright	Buy

Lantern Pharma Inc Aktie (LTRN) Neueste Nachrichten

07:14 AM

Why Lantern Pharma Inc. stock remains resilientNew Guidance & Target Return Focused Stock Picks - Улправда

07:14 AM

Dec 16, 2025

Lantern Pharma (NASDAQ:LTRN) Shares Down 6.4% – Should You Sell? - Defense World

Dec 16, 2025

Dec 14, 2025

Analyst Upgrade: Why Lantern Pharma Inc stock is rated strong buyTrade Entry Summary & Daily Chart Pattern Signals - moha.gov.vn

Dec 14, 2025

Dec 10, 2025

Enlivex Therapeutics and Lantern Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Daily Commercial

Dec 10, 2025

Dec 05, 2025

Lantern Pharma announces LP-184 clinical trial met all primary endpoints - MSN

Dec 05, 2025

Dec 04, 2025

Lantern Pharma (NASDAQ: LTRN) Details Encouraging LP-184 Phase 1a Results Showing Durable Disease Control in Advanced Solid Tumors - Digital Journal

Dec 04, 2025

Will Lantern Pharma Inc. stock benefit from automationTreasury Yields & AI Forecasted Stock Moves - Newser

Dec 04, 2025

Will Lantern Pharma Inc. stock rally after Fed decisionsPortfolio Return Report & Low Volatility Stock Suggestions - Newser

Dec 04, 2025

Lantern Pharma advances AI-Driven cancer drug after successful Phase 1a trial - Proactive financial news

Dec 04, 2025

Dec 03, 2025

Lantern’s cancer drug LP-184 shows promise in phase 1a trial - Investing.com Australia

Dec 03, 2025

Lantern Pharma (LTRN) Advances with Promising Clinical Insights from Phase 1a Study - GuruFocus

Dec 03, 2025

Lantern Pharma reports additional positive LP-184 Phase 1a results showing durable disease control in heavily pre-treated advanced cancer patients - marketscreener.com

Dec 03, 2025

Lantern’s cancer drug LP-184 shows promise in phase 1a trial By Investing.com - Investing.com South Africa

Dec 03, 2025

Lantern Pharma Reports Positive Phase 1a Data For LP-184 In Advanced Solid Tumors - Nasdaq

Dec 03, 2025